The Cymabay recovery continues
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
A turn-up for Spectrum’s book
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
Novavax keeps investors waiting
Those wanting to see whether the US government was right to give Novavax $1.6bn two weeks ago will have to wait a little longer.
Covid-19 vaccine contest turns to T-cell responses
The coronavirus vaccine race now features three front runners with clinical data, and at least one boasts impressive T-cell responses.
Synairgen joins the 2020 coronavirus winners club
A small trial of inhaled interferon marks a 30-fold increase in Synairgen stock since January, but the endpoints warrant scrutiny.
Moderna's Covid-19 vaccine shows promise
But the trade-off between efficacy and tolerability could limit mRNA-1273’s use to those who need it least.
Tecentriq’s ovarian failure highlights a changing market
An Avastin combination draws a blank in the Imagyn-050 study. Will a combo with a Parp inhibitor fare any better?
Obseva shows why red flags are worth heeding
A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Idorsia claims second insomnia hit, but has it done enough?
Daridorexant can't reach the heights of its first pivotal study win, but a pooled analysis could still save it.
